Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GSK3145095 is an orally active inhibitor of RIPK1 with IC50 of 5 nM, with potential immunomodulatory activities and antineoplastic.
説明 | GSK3145095 is an orally active inhibitor of RIPK1 with IC50 of 5 nM, with potential immunomodulatory activities and antineoplastic. |
ターゲット&IC50 | RIP1 kinase:6.3 nM (IC50) |
In vitro | GSK3145095 potently binds to RIP1 with exquisite kinase specificity and has excellent activity in blocking RIP1 kinase-dependent cellular responses.?Highlighting its potential as a novel cancer therapy, the inhibitor was also able to promote a tumor suppressive T cell phenotype in pancreatic adenocarcinoma organ cultures. |
分子量 | 397.38 |
分子式 | C20H17F2N5O2 |
CAS No. | 1622849-43-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 245 mg/mL (616.54 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GSK3145095 1622849-43-7 Apoptosis NF-Κb RIP kinase GSK-3145095 Inhibitor inhibit GSK 3145095 Receptor-interacting protein kinases RIPK inhibitor